Alpha Tau Medical Ltd.
No enriched coverage for $DRTS in the last 7 days.
No SEC Form 4 filings for $DRTS in the last 30 days.
See all $DRTS insider activity →Alpha Tau Medical (DRTS) reported positive early clinical results for Alpha DaRT plus pembrolizumab (Keytruda) in elderly patients with locally advanced or metastatic head and neck squamous cell carcinoma. In nine evaluable patients, the company said ORR was 100% with 44% complete responses and median overall survival of 18.2 months. DRTS shares closed at $13.47.
Alpha Tau Medical Ltd. (Nasdaq: DRTS) said Banner MD Anderson Cancer Center treated the first immunocompromised patient in its ADMIRE trial of intratumoral Alpha DaRT for recurrent cutaneous squamous cell carcinoma. ADMIRE is a prospective, open-label, single-arm study enrolling up to 28 patients, with objective response rate as the primary endpoint.
Oramed Pharmaceuticals said in a shareholder letter it will be added to the Russell 2000 and Russell 3000 indexes effective June 29, 2026. The company reported its Alpha Tau (DRTS) position is up about $128 million to ~$167 million (incl. warrants), and that its Scilex (SCLX) $99.5 million loan has been substantially repaid, with ~$43 million expected by Oct. 2026. Oramed also cited total cash and assets of about $270 million as of March 31, 2026.
Recent DRTS coverage spans technology, financial news and insider activity.
Early, small-sample clinical efficacy signal with a strong ORR and no Alpha DaRT-related serious AEs could drive biotech sentiment and momentum.
First-in-study patient treated in a new immunocompromised cohort expands the clinical narrative beyond ReSTART and may improve perceived addressable market.
DRTS-specific catalysts (Tolmar partnership, ASCO survival data, FDA clearance to complete REGAIN) are supportive for valuation expectations.
A first-in-geography clinical milestone supports execution and expands the perceived addressable trial footprint for Alpha DaRT in GBM.
Insider selling is a modest negative signal, but this is a single Form 4 sale with no stated fundamental catalyst.
alphai scores every news story that mentions DRTS with an AI model for sentiment and relevance, and aggregates insider trades from Alpha Tau Medical Ltd.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Alpha Tau Medical (DRTS) reported positive early clinical results for Alpha DaRT plus pembrolizumab (Keytruda) in elderly patients with locally advanced or metastatic head and neck squamous cell carcinoma. In nine evaluable patients, the company said ORR was 100% with 44% complete responses and median overall survival of 18.2 months. DRTS shares closed at $13.47.
4 min readAlpha Tau Medical Ltd. (Nasdaq: DRTS) said Banner MD Anderson Cancer Center treated the first immunocompromised patient in its ADMIRE trial of intratumoral Alpha DaRT for recurrent cutaneous squamous cell carcinoma. ADMIRE is a prospective, open-label, single-arm study enrolling up to 28 patients, with objective response rate as the primary endpoint.
4 min readOramed Pharmaceuticals said in a shareholder letter it will be added to the Russell 2000 and Russell 3000 indexes effective June 29, 2026. The company reported its Alpha Tau (DRTS) position is up about $128 million to ~$167 million (incl. warrants), and that its Scilex (SCLX) $99.5 million loan has been substantially repaid, with ~$43 million expected by Oct. 2026. Oramed also cited total cash and assets of about $270 million as of March 31, 2026.
6 min readAlpha Tau Medical Ltd. (Nasdaq: DRTS, DRTSW) said it treated the first recurrent glioblastoma patient in Israel and the first outside the U.S. with its Alpha DaRT® system at Hadassah University Medical Center in Jerusalem. The company said the minimally invasive stereotactic procedure used a brain applicator and was completed without unexpected complications under the ALL protocol.
3 min readLevy Raphi (Chief Financial Officer) sold 15,000 shares of Alpha Tau Medical Ltd. (DRTS) at $10.76 ($0.16M total) on 2026-06-03.
2 min readLevy Raphi (Chief Financial Officer) sold 17,500 shares of Alpha Tau Medical Ltd. (DRTS) at $10.90 ($0.19M total) on 2026-06-03.
2 min readAlpha Tau Medical (DRTS) and Tolmar International announced a U.S. collaboration to develop and commercialize Alpha DaRT for prostate cancer. Tolmar will have exclusive U.S. commercialization rights for 20 years from first sale, with an option to expand to bladder cancer after milestones. Tolmar will invest $15m in manufacturing, add $20m equity at $11.99/share, and pay up to $161.5m in milestones; Alpha Tau will supply product at 60% of onward net sales.
4 min readAlpha Tau Medical (NASDAQ:DRTS) traded 527,329 shares on Monday, up 8% from the prior session, after last trading at $10.04 (previous close $10.83). Analysts cited include Citigroup raising its target to $9 (buy) and Barclays starting at $15 (overweight). The company reported EPS of -$0.26 on May 18, missing consensus (-$0.13).
3 min readBarclays upgraded Alpha Tau Medical (NASDAQ:DRTS) to a “strong-buy” rating, according to Zacks.com. Other analysts cited in the article include Citigroup raising its price target to $9 (buy) and HC Wainwright setting $15 (buy). DRTS shares opened at $10.13; last reported EPS was -$0.26, missing consensus -$0.13.
3 min readAlpha Tau (NASDAQ: DRTS) announced its Q1 2026 financial results and significant clinical advancements for its Alpha DaRT cancer therapy, including 100% local disease control in initial U.S. glioblastoma and pancreatic trials. The company also completed enrollment for its pivotal U.S. ReSTART cSCC trial and expanded its IMPACT pancreatic study. Despite widening net losses to $22.9 million, Alpha Tau reported a strong cash position of $80.2 million to support ongoing clinical development and commercialization efforts.
3 min read
